TRENTON – Attorney General Paula T. Dow announced Thursday that New Jersey has entered into a $68.5 million, multi-state settlement agreement with pharmaceutical manufacturer AstraZeneca that resolves allegations the company deceptively marketed its anti-psychotic drug Seroquel.
Under the settlement agreement, New Jersey will receive approximately $1.85 million. Thirty-six states and the District of Columbia also are party to the settlement, described as the largest-ever multi-state, consumer-protection-based pharmaceutical settlement.
According to the AG’s office, AstraZeneca engaged in unfair and misleading practices when it marketed Seroquel for unapproved or off-label uses. The complaint also alleges that AstraZeneca failed to adequately disclose the potential side effects of Seroquel to health care providers, and withheld negative information contained in scientific studies regarding the safety and efficacy of Seroquel.
Among other things, the pharmaceutical company must publicly post payments to physicians on a web site, and have policies to ensure marketing personnel do not have financial incentives tied to off-label uses.
Link to the Complaint:
Link to the Judgment: